General information
Bayer AG
Kaiser-Wilhelm-Allee 1
51368 Leverkusen, North Rhine-Westphalia
Germany
Contact person: Thomas Kornek, Senior Manager, Investor Relations
Company main phone: +49 (214) 301
Website: https://www.bayer.com
Year founded: | 1863
|
Source of foundation: | Independent foundation |
No. of employees: |
Worldwide: 97922 |
Corporate description / mission:
Bayer AG is a German chemical and pharmaceutical company, which focuses on human and veterinary pharmaceuticals; consumer healthcare products; agricultural chemicals and biotechnology products; and polymers. The company's products include adempas, adalat, baytril, etc.
State of ownership: Publicly listed on stock exchange
Headquarters: Yes
IPO (year): 1988
Categorization
Sector: |
- Pharma (fully integrated)
|
Subsector: |
- Anti-infectives
- Antibodies
- Cell therapy
- Gene therapy
- Immunotherapy
- Nucleic acid drugs
- Peptides
- Small molecule therapeutics
- Stem cells
|
Primary therapeutic areas: |
- Cardiovascular / cardiology
- Digestive system / gastroenterology
- Diseases of the blood and blood-forming organs & immune disorders / hematology / immunology
- Diseases of the eye / ophthalmology
- Diseases of the nervous system / neurology
- Endocrine, nutritional and metabolic diseases / endocrinology
- Genitourinary system / Urology
- Infectious and parasitic diseases / infectiology / parasitology
- Musculoskeletal system and connective tissue / Orthopedics
- Neoplasms / cancer / oncology
- Respiratory / pulmonology
- Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified
|
Business model: |
- Manufacturer
- R&D
- Supplier / Distributor
|
Customer segments: |
- Consumers (mass market)
- Hospitals
- Physicians / doctors
|
Summary Products / Services / Technologies
Number of Biotech Products
Phase I: | 23 | |
Phase II: | 9 | |
Phase III: | 12 | |
On the market: | 7 | |
Description of products:
Anetumab Ravtansine for cancer multi indication
Anti-FXI Antibody - Anticoagulation
Anti-TFP1 antibody for Hemophilia
Copanlisib (PI3K Inhibitor) for Cancer, etc
Financing details
Fiscal year (end of) 2022
Revenues: | EUR 50'739.00M | |
R&D expenses: | EUR 6'572.00M | |
Net earnings: | EUR 4'150.00M | |
No. of shares: | 982'424'000 | |
Market cap. / valuation: | EUR 54'612.95M | |